← All indications
Angina, Stable
Persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity. The symptoms are manifestations of MYOCARDIAL ISCHEMIA.
Drugs by status
Approved for this indication (6)
Phase 4 trials (38)
- edoxaban
- allopurinol
- nitroglycerin
- heparin
- dabigatran
- candesartan
- chixiangshen tongxin
- atenolol
- danhong
- guanxin shutong
- ivabradine
- louxiangdan tongxin
- Molsidomine
- ticagrelor
- prasugrel
- ranolazine
- salvianolate
- acetylsalicylic acid
- everolimus
- carvedilol
- rivaroxaban
- pinellia
- cilostazol
- clopidogrel
- danzhen
- chenxiang
- gualou
- xiebai
- chuanxiong
- zhiqiao
- +8 more
Phase 3 trials (9)
Phase 2 trials (7)
Phase 1 trials (11)
Organizations
Organization Involved with Phase 4 Indications (60)
- Takeda
- Gilead Sciences
- AstraZeneca
- Merck Serono
- Merck KGaA
- Ferozsons Laboratories Ltd.
- GlaxoSmithKline
- IHF GmbH - Institut für Herzinfarktforschung
- JW Pharmaceutical
- Shaanxi Buchang Pharmaceutical Co., Ltd
- Therabel Pharma SA/NV
- CardioVascular Research Foundation, Korea
- Fundação Educacional Serra dos Órgãos
- University of Roma La Sapienza
- Huazhong University of Science and Technology
- Ajou University
- Cardiovascular Consultants of Nevada
- China Academy of Chinese Medical Sciences
- Duke University
- Federal University of Rio Grande do Sul
- Gachon University
- Korea University
- Kyung Hee University
- LifeBridge Health
- Mashhad University of Medical Sciences
- Onze Lieve Vrouw Hospital
- Seoul National University
- Sheffield Hallam University
- University of Dundee
- University of Florida
- +30 more
Organization Involved with Phase 3 Indications (22)
- Servier
- Sanofi
- Angionetics Inc.
- Gene Biotherapeutics, Inc.
- Laboratórios Baldacci S.A
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
- Tasly Pharmaceuticals, Inc.
- TSH Biopharm Corporation Limited
- University of Pecs
- Urmia University of Medical Sciences
- Teikyo University
- University of Cincinnati
- St. Antonius Hospital, Nieuwegein
- National Taiwan University
- ATCGen
- Karolinska Institute
- University of Montreal
- Tianjin University
- Technical University of Munich
- Huapont Life Sciences
- Advanced Biosciences Research
- Rajaie Cardiovascular Medical and Research Center
Organization Involved with Phase 2 Indications (15)
- Ablynx
- Amgen
- Bayer
- Sinphar Pharmaceutical Co., Ltd
- Boehringer Ingelheim
- Central South University
- University of London
- University of Aberdeen
- Hunan University of Traditional Chinese Medicine
- Tianjin Medical University
- Chengdu University of Traditional Chinese Medicines
- Shandong University of Traditional Chinese Medicine
- Changchun University of Chinese Medicine
- Heilongjiang University of Traditional Chinese Medicine
- Jilin Academy of Traditional Chinese Medicine
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (9)